JOHN L. HIGGINS - 14 May 2024 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed
Issuer symbol
TECH
Transactions as of
14 May 2024
Transactions value $
-$243,577
Form type
4
Filing time
16 May 2024, 16:17:52 UTC
Previous filing
31 Jan 2024
Next filing
21 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $91.8K +4K +10.93% $22.95 40.6K 14 May 2024 Direct
transaction TECH Common Stock Sale -$335K -4K -9.85% $83.84 36.6K 14 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -4K -25% $0.00 12K 14 May 2024 Common Stock 4K $22.95 Direct
holding TECH Stock Options (Right to Buy) 17K 14 May 2024 Common Stock 17K $21.84 Direct
holding TECH Stock Options (Right to Buy) 15.9K 14 May 2024 Common Stock 15.9K $25.30 Direct
holding TECH Stock Options (Right to Buy) 12.5K 14 May 2024 Common Stock 12.5K $31.26 Direct
holding TECH Stock Options (Right to Buy) 7.59K 14 May 2024 Common Stock 7.59K $44.96 Direct
holding TECH Stock Options (Right to Buy) 8.04K 14 May 2024 Common Stock 8.04K $50.41 Direct
holding TECH Stock Options (Right to Buy) 6.03K 14 May 2024 Common Stock 6.03K $63.92 Direct
holding TECH Stock Options (Right to Buy) 2.53K 14 May 2024 Common Stock 2.53K $128.81 Direct
holding TECH Stock Options (Right to Buy) 3.46K 14 May 2024 Common Stock 3.46K $73.94 Direct
holding TECH Stock Options (Right to Buy) 3.94K 14 May 2024 Common Stock 3.94K $61.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 83.55 to 83.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.